Eton Pharmaceuticals (ETON) Non-Current Debt (2024 - 2025)

Eton Pharmaceuticals' (ETON) quarterly Non-Current Debt came in at $21.8 million in Q4 2025, down 26.98% year-on-year from $29.8 million in Q4 2024, and down 21.1% quarter-over-quarter from $27.6 million in Q3 2025.

Eton Pharmaceuticals (ETON) Non-Current Debt (2024 - 2025) Analysis & Trends

Eton Pharmaceuticals has disclosed Non-Current Debt across 2 years of filings, most recently posting $21.8 million for Q4 2025.

  • Non-Current Debt for Q4 2025 came in at $21.8 million, down 26.98% year-over-year; the trailing twelve-month figure through Dec 2025 was $21.8 million (down 26.98% YoY), and the FY2025 annual result was $21.8 million, down 26.98% from the prior year.
  • Non-Current Debt came in at $21.8 million for Q4 2025 at Eton Pharmaceuticals, down from $27.6 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $29.8 million in Q4 2024 to a low of $21.8 million in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 14.02 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 9.05 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 3.92 Bn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 1.48 Bn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 569.60 Mn
10 Eton Pharmaceuticals 820.42 Mn 794.48 Mn 13.10 Mn 21.77 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 21.77 Mn
Dec 31, 2025 21.77 Mn
Sep 30, 2025 27.59 Mn
Sep 30, 2025 27.59 Mn
Jun 30, 2025 27.41 Mn
Jun 30, 2025 27.41 Mn
Dec 31, 2024 29.81 Mn
Dec 31, 2024 29.81 Mn